Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2004-01-15
2010-10-12
Olson, Eric S (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S055100, C536S123000
Reexamination Certificate
active
07812006
ABSTRACT:
The invention relates to conjugates derived from the reductive amination of the pneumococcus serotype5capsular polysaccharide. The conditions for reductive amination differ from conventional conditions in that they make it possible to avoid the appearance of an undesirable compound which harms the immunogenicity of the conjugates. In carbon NMR spectrum, this undesirable compound is characterized by a resonance signal between 13 and 14 ppm. The aminated polysaccharides used to produce the conjugates therefore have a carbon NMR spectrum lacking a resonance signal between 13 and 14 ppm. The invention offers two conditions for reductive amination. According to a first method, the reductive amination is carried out at a slightly acidic pH (4-6.5) for at the very most 4 hours. According to a second method, the polysaccharide is first of all reduced, then fragmented and, finally, subjected to a reductive amination per se, under conditions which may or may not be conventional. Depending on the method used, the structure of the aminated polysaccharide may vary (conversion or not of the Sug residue of the repeating unit to N-acetylated quinovosamine and to N-acetylated fucosamine); however, these variations, as recorded in carbon NMR spectrometry, have no effect on the immunogenicity.
REFERENCES:
patent: 4761283 (1988-08-01), Anderson
patent: 6045805 (2000-04-01), Moreau
patent: 6596861 (2003-07-01), Moreau
patent: 0 245 045 (1987-11-01), None
patent: 0 477 508 (1992-01-01), None
patent: 0 562 107 (1993-09-01), None
patent: WO 94/29339 (1994-12-01), None
patent: WO 98/51339 (1998-11-01), None
patent: WO 00/55210 (2000-09-01), None
patent: WO 00/56358 (2000-09-01), None
Jansson et al. “Structural studies of the capsular polysaccharide fromStreptococcus pneumoniaeType 5.” Carbohydrate Research, 140, 101-110, 1985.
Pinta et al., 2009, Chem. Eur. J., 15, 9747-9754, Identification and Role of a 6-Deoxy-4-Keto-Hexosamine in the Lipopolysaccharide Outer Core ofYersinia enterocoliticaSerotype O:3.
Jansson, Per-Erik et al., “Structural Studies of the Capsular Polysaccharide FromStreptococcus pneumoniaeType 5,” Carbohydrate Research, 140 (1985), pp. 101-110.
Gotschlich, Emil C. et al., “Human Immunity to the Meningococcus, III. Preparation and Immunochemical Properties of the Group A, Group B, and Group C Meningococcal Polysaccharides”, Journal of Exp. Med., 129 (1969) 1349-1365.
Jones, Christopher et al., “Full Assignment of the Proton and Carbon NMR Spectra and Revised Structure for the Capsular Polysaccharide fromStreptococcus pneumoniaeType 17F”, Carbohydrate Research, 325 (2000) 192-201.
Del Guercio, Marie-France et al., “Potent Immunogenic Short Linear Peptide Constructs Composed of B Cell Epitopes and Pan DR T Helper Epitopes (PADRE) for Antibody Responses In Vivo”, Vaccine, vol. 15, No. 4, (1997) pp. 441-448.
Laferriere, Craig A., et al., “The Synthesis ofStreptococcus pneumoniaPolysaccharide—Tetanus Toxoid Conjugates and the Effect of Chain Length On Immunogenicity,” Vaccine, vol. 15, No. 2 (1997) pp. 179-186.
Danve Emilie
Mistretta Noëlle
Moreau Monique
Aventis Pasteur S.A.
McDonnell Boehnen & Hulbert & Berghoff LLP
Olson Eric S
LandOfFree
Conjugates obtained by reductive amination of the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Conjugates obtained by reductive amination of the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Conjugates obtained by reductive amination of the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4200275